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research purposes, but not used for clinical decision making. 
Doses to the PTV, lung, heart and LAD were recorded. Four 
patient groups were identified for comparison: those who had 
at least one heart parameter worse with DIBH, minimal 
benefit arbitrarily defined as less than 20%, moderate benefit 
defined as between 20%-70% and a major benefit defined as 
greater than 70%. 
 
Results: Data was collected for a total of 70 patients. 
Overall, using DIBH, lung volume increased on average by 68% 
(range: 18.5% – 124.3%) while the heart volume in the 
treatment field was reduced by an average 69.5%. The LAD 
volume within the treatment field was reduced by 53%. The 
degree of benefit for heart and LAD doses is outlined in table 
1. 10% had at least one heart parameter worse with DIBH. 
Where the mean heart dose was higher all other heart 
constraints were worse. Five patients had an increase in the 
heart volume and maximum heart distance in the treatment 
field.  
 
 
 
Conclusion: Patients where DIBH was detrimental to heart 
dose constraints, no clear correlation could be drawn to 
identify this cohort of patients. Lung volume or percentage 
increase did not necessarily lead to more favourable 
outcomes, thus could not be used as a criteria for patient 
selection for DIBH. We aim to establish further predictive 
criteria in the second phase of this study. Until such time 
dual planning remains essential to identify patients who 
should not be offered DIBH. 
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Purpose or Objective: To establish whether photon or 
electron beams provide better dose coverage to tumour bed 
sites in different regions of the breast. 
 
Material and Methods: 10 patient data sets were selected 
from a trial cohort, 2 patients each with tumour beds in one 
of 5 regions within the breast – Superior Lateral Quadrant 
(SQL), Superior Medial Quadrant (SMQ), Inferior Lateral 
Quadrant (ILQ), Inferior Medial Quadrant (IMQ) and the 
Central Quadrant. The dose to the whole breast treatment of 
50Gy in 25 fractions was combined with a boost plan to the 
tumour bed of either photons or electrons with a dose of 
16Gy in 8 fractions. Dose to the PTV, lung, heart and breast 
tissues outside the tumour bed were assessed by using DVHs. 
 
Results: Tumours in the SLQ received better dose coverage 
by the photon boost plans. In all other areas of the breast the 
tumour bed coverage objectives were met with either 
photons or electrons.The target coverage in the combined 
plans was at least the same as or better than electrons with 
photon beams in all cases (Figure1). Electron beam coverage 
is dependent on surface contour regularity and tumour 
geometric shape, particularly if the PTV is not perpendicular 
to the skin surface and so requiring higher electron energies 
for PTV coverage at the deep margin. Lung had consistently 
lower doses with photon boost plans as the higher electron 
energies selected for target coverage in some plans increased 
lung dose (Figure2). The breast outside the tumour bed 
received lower doses with photon boosts. The heart doses 
were not consistently lower with either modality. 
 
 
 
Conclusion: Electrons were a less favourable modality for 
SLQ tumours, but either photons or electrons could be 
suitable for treating tumours in other regions of the breast in 
terms of target coverage and organ sparing. As photon boosts 
provided the same as or better coverage than electrons in 
combined plans, it would be feasible to use photons for all 
boosts. However, individualised planning is necessary to 
account for tumour position in relation to normal anatomy, 
surface contour and geometrical shaping of the tumour bed 
to optimise PTV coverage and organ sparing. If using 
electrons particular attention must be paid to the use of 
bolus for beams planned on irregular surface contours. 
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Purpose or Objective: This study was to quantify the 
reduced dose of right lung and right breast tissue by modified 
volumetric modulated arc therapy (MVMAT) for advanced 
left-side breast cancer including lymph node irradiation. 
 
Material and Methods: For all cases, the clinical target 
volume (CTV) consisted of the left breast, axillary lymph 
nodes, internal mammary chain lymph nodes, infraclavicular 
lymph nodes, and supraclavicular lymph nodes. 7 patients of 
MVMAT and 5 patients of volumetric modulated arc therapy 
(VMAT) were generated with the Eclipse Version11 treatment 
planning system. VMAT plans were generated using a five full 
rotation without avoidance sector. MVMAT plans were 
generated using a five partial rotation with avoidance 
sector.Two half arcs were for supraclavicular lymph nodes. 
Gantry angle started at 179 degree, stopped at 335 degree, 
and the 60-120 degree was set to be avoidance sector. 
